The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

Core Viewpoint - Capricor Therapeutics, Inc. is facing allegations of misleading investors regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1] Group 1: Allegations and Legal Actions - The class period for the allegations against Capricor is from October 9, 2024, to July 10, 2025 [1] - Defendants allegedly provided misleading information about Capricor's ability to obtain a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from the Phase 2 HOPE-2 trial [1] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA, Capricor's stock price fell from $11.40 to $7.64 per share [1] Group 2: Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by September 15, 2025 [2] - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2] Group 3: Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [3] - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions by companies [3]